FI
PLX icon

Finivi Inc’s Protalix BioTherapeutics PLX Stock Holding History

Finivi Inc’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,544
Closed -$14.8K – 93
2024
Q3 		$14.8K Hold
14,544
– – 0.01% 85
2024
Q2 		$17K Hold
14,544
– – 0.01% 90
2024
Q1 		$18.3K Hold
14,544
– – 0.02% 84
2023
Q4 		$25.9K Buy
+14,544
New +$22.6K 0.03% 90
2021
Q4 		$12.1K Buy
+14,544
New +$15.2K 0.01% 75

Other funds holding PLX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Finivi Inc's PLX Position: Q4 2024 in Review

Finivi Inc sold out of Protalix BioTherapeutics (PLX) in Q4 2024, closing a stake of 14,544 shares — an estimated $14.8K sold.

Finivi Inc first reported a position in PLX in Q4 2021 and held it in 5 quarters. The position peaked at $25.9K in Q4 2023. 45 funds tracked by Wall St. Rank hold PLX as of Q4 2024.

  • Finivi Inc reported no remaining Protalix BioTherapeutics position as of Q4 2024 after selling out during the quarter.
  • Finivi Inc sold 14,544 Protalix BioTherapeutics shares in Q4 2024, an estimated $14.8K.
  • Finivi Inc first reported a position in Protalix BioTherapeutics in Q4 2021 and held it in 5 quarters.
  • Finivi Inc's Protalix BioTherapeutics position peaked at $25.9K in Q4 2023.
  • 45 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2024.

Based on Finivi Inc's 13F filing for Q4 2024, filed 19 Dec 2025.